The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Open accessAbstract
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾ 10 7 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% ( P =0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P =0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationvan Dongen, J. J. M., Langerak, A. W., Brüggemann, M., Evans, P. A. S., Hummel, M., Lavender, F. L., Delabesse, E., Davi, F., Schuuring, E., García-Sanz, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403202 · Cited by 3,043
Self-citationon behalf of the EuroFlow Consortium (EU-FP6, L.-C.-2.-0., van Dongen, J. J. M., Lhermitte, L., Böttcher, S., Almeida, J., van der Velden, V. H. J., Flores-Montero, J., Rawstron, A., Asnafi, V, Lécrevisse, Q., et al. (2012) · Leukemia · doi:10.1038/leu.2012.120 · Cited by 934
Self-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
on behalf of the EuroFlow Consortium (EU-FP6, L.-C.-2.-0., Kalina, T., Flores-Montero, J., van der Velden, V. H. J., Martin-Ayuso, M., Böttcher, S., Ritgen, M., Almeida, J., Lhermitte, L., Asnafi, V, et al. (2012) · Leukemia · doi:10.1038/leu.2012.122 · Cited by 783
Self-citationRöllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Rawstron, A. C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., et al. (2008) · Haematologica · doi:10.3324/haematol.11080 · Cited by 513
Self-citationvan Dongen, J. J. M., van der Velden, V. H. J., Brüggemann, M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2015-03-580027 · Cited by 511
Self-citationMartinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Self-citationRawstron, A. C., Child, J. A., de Tute, R. M., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Feyler, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2119 · Cited by 415
Ladetto, M., Brüggemann, M., Monitillo, L., Ferrero, S., Pepin, F., Drandi, D., Barbero, D., Palumbo, A., Passera, R., Boccadoro, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.375 · Cited by 304
Paiva, B., Gutiérrez, N. C., Rosiñol, L., Vídriales, M.-B., Montalbán, M.-Á., Martínez-López, J., Mateos, M.-V., Cibeira, M.-T., Cordón, L., Oriol, A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-370460 · Cited by 300
Self-citationNew criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Self-citationLahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M. T., Carrera, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9721 · Cited by 279
Self-citationGay, F., Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., Genuardi, M., Romano, A., Liberati, A. M., Siniscalchi, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307645 · Cited by 263
Flores‐Montero, J., de Tute, R., Paiva, B., Perez, J. J., Böttcher, S., Wind, H., Sanoja, L., Puig, N., Lecrevisse, Q., Vidriales, M. B., et al. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21265 · Cited by 261
Self-citationSonneveld, P., Goldschmidt, H., Rosiñol, L., Bladé, J., Lahuerta, J. J., Cavo, M., Tacchetti, P., Zamagni, E., Attal, M., Lokhorst, H. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4626 · Cited by 248
Self-citationCuring myeloma at last: defining criteria and providing the evidence
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G. J., & Crowley, J. (2014) · Blood · doi:10.1182/blood-2014-07-552059 · Cited by 235
Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
Self-citationPaiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1967 · Cited by 233
Self-citationSelecting fluorochrome conjugates for maximum sensitivity
Maecker, H. T., Frey, T., Nomura, L. E., & Trotter, J. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20092 · Cited by 216
Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 211
Rawstron, A. C., Davies, F. E., DasGupta, R., Ashcroft, A. J., Patmore, R., Drayson, M. T., Owen, R. G., Jack, A. S., Child, J. A., & Morgan, G. J. (2002) · Blood · doi:10.1182/blood-2001-12-0297 · Cited by 210
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting
Arroz, M., Came, N., Lin, P., Chen, W., Yuan, C., Lagoo, A., Monreal, M., de Tute, R., Vergilio, J., Rawstron, A. C., et al. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21228 · Cited by 194
Self-citationSarasquete, M. E., García‐Sánz, R., González, D., Martínez‐López, J., Mateo, G., Martı́nez, P., Ribera, J., Hernández, J. M., Lahuerta, J. J., Órfão, A., et al. (2005) · PubMed · Cited by 181
Self-citationRawstron, A. C., Gregory, W. M., de Tute, R. M., Davies, F. E., Bell, S. E., Drayson, M. T., Cook, G., Jackson, G. H., Morgan, G. J., Child, J. A., et al. (2015) · Blood · doi:10.1182/blood-2014-07-590166 · Cited by 178
Puig, N., Sarasquete, M. E., Balanzategui, A., Martínez, J., Paiva, B., García, H., Fumero, S., Jiménez, C., Alcoceba, M., Chillón, M. C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.217 · Cited by 170
Self-citationPrinciples of minimal residual disease detection for hematopoietic neoplasms by flow cytometry
Wood, B. L. (2016) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21239 · Cited by 166
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Overview of clinical flow cytometry data analysis: recent advances and future challenges
Pedreira, C. E., da Costa, E. S., Lécrevisse, Q., van Dongen, J. J. M., & Órfão, A. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.04.008 · Cited by 156
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva, B., Cedena, M., Puig, N., Arana, P., Vídriales, M., Cordón, L., Flores-Montero, J. A., Gutierrez, N. C., Martín-Ramos, M.-L., Martínez‐López, J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705319 · Cited by 155
Self-citationConsensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Stetler‐Stevenson, M., Paiva, B., Stoolman, L. M., Lin, P., Jorgensen, J. L., Órfão, A., van Dongen, J. J. M., & Rawstron, A. C. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21249 · Cited by 139
Self-citationMinimal residual disease in multiple myeloma: bringing the bench to the bedside
Mailankody, S., Korde, N., Lesokhin, A. M., Lendvai, N. K., Hassoun, H., Stetler‐Stevenson, M., & Landgren, O. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.239 · Cited by 118
Usmani, S. Z., Crowley, J. J., Hoering, A., Mitchell, A., Waheed, S., Nair, B. P., Alsayed, Y. M., Vanrhee, F., & Barlogie, B. (2012) · Leukemia · doi:10.1038/leu.2012.160 · Cited by 114
Paiva, B., Chandía, M., Vídriales, M., Colado, E., Caballero‐Velázquez, T., Escalante, F., de Coca, A. G., Montes, M.-C., García‐Sánz, R., Ocio, E. M., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567909 · Cited by 98
Self-citationMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
Lonial, S., Durie, B. G. M., Palumbo, A. P., & Miguel, J. F. S. (2015) · Leukemia · doi:10.1038/leu.2015.223 · Cited by 98
Self-citationLadetto, M., Donovan, J. W., Harig, S., Weller, E. A., Trojan, A., Poor, C., Schlossman, R. L., Anderson, K. C., & Gribben, J. G. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70006-1 · Cited by 97
Generation of flow cytometry data files with a potentially infinite number of dimensions
Pedreira, C. E., da Costa, E. S., Bárrena, S., Lécrevisse, Q., Almeida, J., van Dongen, J. J. M., & Órfão, A. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20608 · Cited by 93
Promising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 93
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Flanders, A. W., Stetler‐Stevenson, M., & Landgren, O. (2013) · Blood · doi:10.1182/blood-2013-05-506170 · Cited by 92
Pedreira, C. E., da Costa, E. S., Almeida, J., Fernández, C., Quijano, S., Flores-Montero, J. A., Bárrena, S., Lécrevisse, Q., van Dongen, J. J. M., & Orfao, A. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20638 · Cited by 65
Self-citationTreatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, M., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez‐López, J., Bladé, J., Lahuerta, J. J., García‐Sánz, R., & Miguel, J. F. S. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.001 · Cited by 55
Self-citationAssessment of minimal residual disease in myeloma and the need for a consensus approach
Rawstron, A. C., Paiva, B., & Stetler‐Stevenson, M. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21272 · Cited by 46
Self-citationIs This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Paiva, B., Puig, N., García‐Sánz, R., & Miguel, J. F. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2841 · Cited by 45
Self-citationRoyston, D. J., Gao, Q., Nguyen, N., Maslak, P. G., Doǧan, A., & Roshal, M. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw052 · Cited by 43
Deep response in multiple myeloma: a critical review.
Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J. (2015) · BioMed Research International · doi:10.1155/2015/832049 · Cited by 40
Silvennoinen, R. H., Lundán, T., Kairisto, V., Pelliniemi, T., Putkonen, M., Anttila, P. M., Huotari, V., Mäntymaa, P., Siitonen, S. M., Uotila, L., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.69 · Cited by 36
Martínez‐López, J., Fernández‐Redondo, E., García‐Sánz, R., Montalbán, M.-Á., Martínez‐Sánchez, P., Pavia, B., Mateos, M., Rosiñol, L., Martín, M., Ayala, R. M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12576 · Cited by 30
Self-citationRawstron, A. C., Tute, R. M. D., Haughton, J., & Owen, R. G. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21271 · Cited by 26
Myeloma minimal residual disease testing in the United States: Evidence of improved standardization
Salem, D., Stetler‐Stevenson, M., Yuan, C. M., & Landgren, O. (2016) · American Journal of Hematology · doi:10.1002/ajh.24540 · Cited by 20
Puig, N., Sarasquete, M. E., Alcoceba, M., Balanzategui, A., Chillón, C., Sebastián, E., Díaz, M. G., Miguel, J. F. S., & García‐Sánz, R. (2012) · European Journal Of Haematology · doi:10.1111/ejh.12000 · Cited by 14
Self-citationInitial treatment of transplant-ineligible patients in multiple myeloma
Mateos, M., Leleu, X. P., Palumbo, A. P., & Miguel, J. F. S. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2014.864230 · Cited by 11
Self-citation
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Self-citationB cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778
Heuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Metadata
- Authors
- Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., Jimenez, C., González, M., Martínez-López, J., Corral-Mateos, A., Grigore, G.-E., Fluxá, R., Pontes, R., Caetano, J., Sedek, L., del Cañizo, M.-C., Bladé, J., Lahuerta, J.-J., Aguilar, C., Bárez, A., García-Mateo, A., Labrador, J., Leoz, P., Aguilera-Sanz, C., San-Miguel, J., Mateos, M.-V., Durie, B., van Dongen, J. J. M., & Orfao, A.
- Venue
- Leukemia
- Published
- 2017-01-20
- Volume
- 31
- Issue
- 10
- Pages
- 2094-2103
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2579739608
- Cited by
- 676
- References
- 52
- FWCI
- 42.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.